1. Friedlander AL, Lynch D, Dyar LA, Bowler RP. Phenotypes of chronic obstructive pulmonary disease. COPD 2007; 4: 355–84.
2. Buist AS, McBurnie MA, Vollmer WM et al. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet 2007; 370: 741–50.
3. Mannino DM, Homa DM, Akinbami LJ et al. Surveillance for asthma − United States, 1980–1999. MMWR Surveill Summ 2002; 51: 1–13.
4. Barnes PJ. Chronic obstructive pulmonary disease: a growing but neglected global epidemic. PLoS Med 2007; 4: e112.
5. Parnham MJ. Immunomodulatory effects of antimicrobials in the therapy of respiratory tract infections. Curr Opin Infect Dis 2005; 18: 125–31.
6. Kudoh S, Azuma A, Yamamoto M et al. Improvement of survival in patients with diffuse panbronchiolitis treated with low-dose erythromycin. Am J Respir Crit Care Med 1998; 157: 1829–32.
7. Takizawa H, Desaki M, Ohtoshi T et al. Erythromycin modulates IL-8 expression in normal and inflamed human bronchial epithelial cells. Am J Respir Crit Care Med 1997; 156: 266–71.
8. Crosbie PAJ, Woodhead MA. Long-term macrolide therapy in chronic inflammatory airway diseases. Eur Respir J 2009; 33: 171–81.
9. Vanaudenaerde BM, Meyts I, Vos R et al. A dichotomy in bronchiolitis obliterans syndrome after lung transplantation revealed by azithromycin therapy. Eur Respir J 2008; 32: 832–42.
10. Saeki T, Ueda K, Tanigawara Y et al. Human P-glycoprotein transports cyclosporin A and FK506. J Biol Chem 1993; 268: 6077–80.
11. Yee GC, McGuire TR. Pharmacokinetic drug interactions with cyclosporin (Part I). Clin Pharmacokinet 1990; 19: 319–32.
12. Gladue RP, Bright GM, Isaacson RE, Newborg MF. In vitro and in vivo uptake of azithromycin (CP-62,993) by phagocytic cells: possible mechanism of delivery and release at sites of infection. Antimicrob Agents Chemother 1989; 33: 277–82.
13. Tamaoki J, Kadota J, Takizawa H. Clinical implications of the immunomodulatory effects of macrolides. Am J Med 2004; 117 (Suppl.): 9A 5S–11S.
14. Cazzola M, Blasi F, Tarsia P et al. Role of macrolides as immunomodular agents. Clin Pulm Med 2006; 13: 274–81.
15. Murphy DM, Forrest IA, Ward C et al. Effect of azithromycin on primary bronchial epithelial cells derived from stable lung allografts. Thorax 2007; 62: 834.
16. Vanaudenaerde BM, Wuyts WA, Geudens N et al. Macrolides inhibit IL17-induced IL8 and 8-isoprostane release from human airway smooth muscle cells. Am J Transplant 2007; 7: 76–81.
17. Baumann U, Fischer JJ, Gudowius P et al. Buccal adherence of Pseudomonas aeruginosa in patients with cystic fibrosis under long-term therapy with azithromycin. Infection 2001; 29: 7–11.
18. Mitsuya Y, Kawai S, Kobayashi H. Influence of macrolides on guanosine diphospho-D-mannose dehydrogenase activity in Pseudomonas biofilm. J Infect Chemother 2000; 6: 45–50.
19. Kawamura-Sato K, Iinuma Y, Hasegawa T et al. Effect of subinhibitory concentrations of macrolides on expression of flagellin in Pseudomonas aeruginosa and Proteus mirabilis. Antimicrob Agents Chemother 2000; 44: 2869–72.
20. Wolter J, Seeney S, Bell S et al. Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomized trial. Thorax 2002; 57: 212–6.
21. Saiman L, Marshall BC, Mayer-Hamblett N et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 2003; 290: 1749–56.
22. Southern KW, Barker PM, Solis A. Macrolide antibiotics for cystic fibrosis. Cochrane Database Syst Rev 2005; 4.
23. Khan TZ, Wagener JS, Bost T et al. Early pulmonary inflammation in infants with cystic fi brosis. Am J Respir Crit Care Med 1995; 151: 1075–82.
24. Trulock EP, Edwards LB, Taylor DO et al. The Registry of the International Society for Heart and Lung Transplantation: Twentieth offi cial adult lung and heart-lung transplant report – 2003. J Heart Lung Trans 2003; 22: 625–35.
25. Jaffe A, Francis J, Rosenthal M et al. Long-term azithromycin may improve lung function in children with cystic fi brosis. Lancet 1998; 351: 420.
26. Saiman L, Mayer-Hamblett N, Campbell P et al. Heterogeneity of treatment response to azithromycin in patients with cystic fibrosis. Am J Respir Crit Care Med 2005; 172: 1008–12.
27. Barker AF. Bronchiectasis. New Eng J Med 2003; 346: 1383–93.
28. Angrill J, Agusti C, De Celis R et al. Bronchial inflammation and colonization in patients with clinically stable bronchiectasis. Am J Respir Crit Care Med 2001; 164: 1628–32.
29. Tsang KW, Chan KN, Ho PL et al. Sputum elastase in steady-state bronchiectasis. Chest 2000; 117: 420–6.
30. Ho PL, Chan KN, Ip MSM et al. The effect of Pseudomonas aeruginosa infection on clinical parameters in steady-state bronchiectasis. Chest 1998; 114: 1594–8.
31. Koh YY, Lee MH, Sun YH et al. Effect of roxithromycin on airway responsiveness in children with bronchiectasis: a double-blind, placebo-controlled study. Eur Respir J 1997; 10: 994–9.
32. Tsang KWT, Ho PI, Chan KN et al. A pilot study of low-dose erythromycin in bronchiectasis. Eur Resp J 1999; 13: 361–4.
33. Davies G, Wilson R. Prophylactic antibiotic treatment of bronchiectasis with azithromycin. Thorax 2004; 59: 540–1.
34. Wong C, Jayaram L, Karalus N et al. Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial. Lancet 2012; 380: 660–7.
35. Gomez J, Baсos V, Simarro E et al. Estudio prospective y comparative (1994–1998) sobre la infl uencia del tratamiento corto profilactico con azitromicina en pacientes con EPOC evolucionada. Rev Esp Quimioterap 2000; 13: 379–83.
36. Seemungal TAR, Wilkinson TMA, Hurst JR et al. Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations. Am J Respir Crit Care Med 2008; 178: 1139–47.
37. Blasi F, Bonardi D, Aliberti S et al. Long-term azithromycin use in patients with chronic obstructive pulmonary disease and tracheostomy. Pulmon Pharmacol Therap 2010; 23: 200–7.
38. Mygind LH, Pedersen C, Vestbo J et al. A randomized, placebo-controlled 3 years study of prophylactic azithromycin in 575 patients with chronic obstructive pulmonary disease. Eur Respir J 2010; 36 (Suppl. 54): 1018s.
39. Albert RK, Connett J, Bailey WC et al. Azithromycin for prevention of exacerbations of COPD. N Engl J Med 2011; 365: 689–98.
40. Ryu JH, Myers JL, Swensen SJ. Bronchiolar Disorders. Am J Respir Crit Care Med 2003; 168: 1277–92.
41. Wright JL, Cagle P, Chung A et al. Diseases of the small airways. Am Rev Respir Dis 1992; 146: 240–62.
42. Boehler A, Estenne M. Post-transplant bronchiolitis obliterans. Eur Respir J 2003; 22: 1007–18.
43. Griffith BP, Paradis IL, Zeevi A et al. Immunologically mediated disease of the airways after lung transplantation. Ann Surg 1988; 208: 371–8.
44. Gerhardt SG, McDyer JF, Girgis RE et al. Maintenance azithromycin therapy for bronchiolitis obliterans syndrome: results of a pilot study. Am J Respir Crit Care Med 2003; 168: 121–5.
45. Verleden GM, Dupont LJ. Azithromycin therapy for patients with bronchiolitis obliterans syndrome after lung transplantation. Transplantation 2004; 77: 1465–7.
46. Yates B, Murphy DM, Forrest IA et al. Azithromycin reverses airflow obstruction in established bronchiolitis obliterans syndrome. Am J Respir Crit Care Med 2005; 172: 772–5.
47. Hajari A, Leon K, Gaggar A et al. Combination therapy utilizing azithromycin and photopheresis for bronchiolitis obliterans syndrome following lung transplantion. Chest 2007; 132 (Suppl.): 431S.
48. National Asthma Education and Prevention Program. Expert Panel Report 3 (EPR-3): Guidelines for the diagnosis and management of asthma-summary report 2007. J Allergy Clin Immunol 2007; 120 (Suppl. 5): S94–S138.
49. Sutherland ER, Martin RJ. Asthma and atypical bacterial infection. Chest 2007; 132: 1962–6.
50. Szefler SJ, Rose JQ, Ellis EF et al. The effect of troleandomycin on methylprednisolone elimination. J Allergy Clin Immunol 1980; 66: 447–51.
51. Black PN, Blasi F, Jenkins CR et al. Trial of roxithromycin in subjects with asthma and serological evidence of infection with Chlamydia pneumoniae. Am J Respir Crit Care Med 2001; 164: 536–41.
52. Kraft M, Cassell GH, Pak J, Martin RJ. Mycoplasma pneumoniae and Chlamydia pneumoniae in asthma: effect of clarithromycin. Chest 2002; 121: 1782–8.
53. Simpson JL, Powell H, Boyle MJ et al. Clarithromycin targets neutrophilic airway inflammation in refractory asthma. Am J Respir Crit Care Med 2008; 177: 148–55.
54. Kostadima E, Tsiodras S, Alexopoulos EI et al. Clarithromycin reduces the severity of bronchial hyperresponsiveness in patients with asthma. Eur Respir J 2004; 23: 714–7.
55. Amayasu H, Yoshida S, Ebana S et al. Clarithromycin suppresses bronchial hyperresponsiveness associated with eosinophilic inflammation in patients with asthma. Ann Allergy Asthma Immunol 2000; 84: 594–8.
56. Hahn DL, Plane MB, Mahdi OS, Byrne GI. Secondary outcomes of a pilot randomized trial of azithromycin treatment for asthma. PLoS Clin Trials 2006; 1: e11.
57. Hahn DL, Grasmick M, Hetzel S, Yale S. Azithromycin for bronchial asthma in adults. An effectiveness trial. J Am Board Fam Med 2012; 25: 442–59.
58. Белоцерковская Ю.Г, Казаков С.П., Синопальников А.И. Бронхиальная астма, ассоциированная с Chlamydia pneumoniae инфекцией. Клин. микроб. антимикроб. химиотер. 2007; 9: 233–43.
59. Richeldi L, Ferrara G, Fabbri LM et al. Macrolides for chronic asthma. Cochrane Database Syst Rev 2005; 4: CD002997.
60. Martínez JA, Horcajada JP, Almela M et al. Addition of a macrolide to a beta-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia. Clin Infect Dis 2003; 36: 389–95.
61. Metersky ML, Ma A, Houck PM, Bratzler DW. Antibiotics for bacteremic pneumonia: improved outcomes with macrolides but not fluoroquinolones . Chest 2007; 131: 466–73.
62. Giamarellos-Bourboulis EJ, Pechère JC, Routsi C et al. Effect of clarithromycin in patients with sepsis and ventilator-associated pneumonia. Clin Infect Dis 2008; 46: 1157–64.
63. Wheeler AP, Bernard G. Acute lung injury and the acute respiratory distress syndrome: a clinical review. Lancet 2007; 369: 1553–64.
64. Tamaoki J, Tagaya E, Yamawaki I et al. Effect of erythromycin on endotoxin-induced microvascular leakage in the rat trachea and lungs. Am J Respir Crit Care Med 1995; 151: 1582–8.
65. Walkey AJ, Wiener RS. Macrolide antibiotics and survival in patients with acute lung injury. Chest 2012; 141: 1153–9.
66. Klugman KP, Lonks JR. Hidden epidemic of macrolide-resistant pneumococci. Emer Inf Dis 2005; 11: 802–7.
67. Vanderkooi OG, Low DE, Green K et al. Predicting antimicrobial resistance in invasive pneumococcal infections. Clin Inf Dis 2005; 40: 1288–97.
68. Aberg JA, Wong MK, Flamm R et al. Presence of macrolide resistance in respiratory flora of HIV-infected patients receiving either clarithromycin or azithromycin for Mycobacterium avium complex prophylaxis. HIV Clin Trials 2001; 2: 453–9.
69. Kasahara K, Kita E, Maeda K et al. Macrolide resistance of Streptococcus pneumoniae isolated during long-term macrolide therapy: difference between erythromycin and clarithromycin. J Infect Chemother 2005; 11: 112–4.
70. Cymbala AA, Edmonds LC, Bauer MA et al. The disease-modifying effects of twice-weekly oral azithromycin in patients with bronchiectasis. Treat Respir Med 2005; 4: 117–22.
71. Iannini PB. Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QT interval. Expert Opin Drug Saf 2002; 1: 121–8.
72. Milberg P, Eckardt L, Bruns HJ et al. Diveregent proarrhythmic potential of macrolide antibiotics despite similar QT prolongation: fast phase 3 repolarization prevents early afterdepolarizations and torsade de pointes. J Pharmacol Exp Therapeut 2002; 303: 218–25.
73. Ray WA, Murray KT, Hall K et al. Azithromycin and the risk of cardiovascular death. N Engl J Med 2012; 366: 1881–90.
74. Haydon RC, Thelin JW, Davis WE. Erythromycin ototoxicity: analysis and conclusions based on 22 case reports. Otolaryngol Head Neck Surg 1984; 92: 678–84.
75. Swanson DJ, Sung RJ, Fine MJ et al. Erythromycin ototoxicity: prospective assessment with serum concentrations and audiograms in a study of patients with pneumonia. Am J Med 1992; 92: 61–8.
76. Wallace MR, Miller LK, Nguyen MT et al. Ototoxicity with azithromycin. Lancet 1994; 343: 241.

С.Н.Авдеев

ФГУ Научно-исследовательский институт пульмонологии Федерального медико-биологического агентства России